Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.

By Hideaki Takahashi, Y. Tada, T. Saotome, K. Akazawa, H. Ojiri, C. Fushimi, T. Masubuchi, T. Matsuki, Kaori Tani, R. Osamura and 6 more. 2019

Subfields: Oncology, Otorhinolaryngology

Citations in the corpus

• Trastuzumab-deruxtecan shows interesting disease control in a multitreated patient with ERBB2 amplified parotid carcinoma, a case report (2025, unknown): “21,22 A pooled analysis from Takahashi et al. 19 consisted of 17 patients with salivary gland cancer with 9 cases of salivary duct cancer and 2 cases of adenocarcinoma treated with T-Dxd.”